Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Wyeth Effexor Promotions Cited For Superiority Claims In FDA Letter

This article was originally published in The Pink Sheet Daily

Executive Summary

The ad division letter follows an Office of Personnel Management Inspector General investigation into Wyeth's Effexor marketing practices. FDA asserts that Wyeth's claims of superiority to SSRIs are unsubstantiated.

You may also be interested in...



Effexor Script Growth Will Double Antidepressant Market Rate, Wyeth Predicts

Effexor XR scripts grew 4% in the third quarter, compared to 2% growth for the category, Wyeth says. Sales of the antidepressant franchise jumped 46% in the U.S. in the third quarter. The company predicts “black box” class warning will not significantly impact Effexor, which is not advertised on TV.

Effexor Script Growth Will Double Antidepressant Market Rate, Wyeth Predicts

Effexor XR scripts grew 4% in the third quarter, compared to 2% growth for the category, Wyeth says. Sales of the antidepressant franchise jumped 46% in the U.S. in the third quarter. The company predicts “black box” class warning will not significantly impact Effexor, which is not advertised on TV.

GSK Paxil CR Ad Medicalizes "Ordinary" Anxiety, FDA Says

TV ads "broaden" use of the antidepressant beyond social anxiety disorder and into attributes that "do not generally require psychopharmacological treatment," FDA ad division letter says. Risk information is minimized by distractions and failure to note contraindications, FDA says.

Related Content

Topics

UsernamePublicRestriction

Register

OM005224

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel